Need To Accelerate Your In Vivo CAR-T? You Need Lonza.

In vivo CAR-T recasts cell therapy as a delivery problem as much as a biological one. Clinical programs now run on both lentiviral vectors and mRNA-LNP systems, yet scalable, well-characterized, regulatory-ready candidates remain in short supply. Lonza lays out where LVV and RNA-LNP support diverge.

On the viral side, that means platform processes, deep vector characterization, and established CMC frameworks. On the LNP side, targeted delivery takes priority: antibody and ligand conjugation, access to clinically validated ionizable lipids, and multi-CQA analytics meant to surface process problems early, with manufacturing running from DNA template through fill-finish.

Learn more about what Lonza can do for your program by downloading the brochure below.